Advertisement
UK markets closed
  • NIKKEI 225

    38,876.71
    -258.08 (-0.66%)
     
  • HANG SENG

    17,937.84
    -238.50 (-1.31%)
     
  • CRUDE OIL

    78.58
    +0.68 (+0.87%)
     
  • GOLD FUTURES

    2,354.30
    +27.70 (+1.19%)
     
  • DOW

    38,783.40
    +35.98 (+0.09%)
     
  • Bitcoin GBP

    54,143.61
    +2,333.37 (+4.50%)
     
  • CMC Crypto 200

    1,434.29
    +39.25 (+2.81%)
     
  • NASDAQ Composite

    17,647.29
    +303.74 (+1.75%)
     
  • UK FTSE All Share

    4,482.40
    +38.33 (+0.86%)
     

Calculating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

Key Insights

  • The projected fair value for Alliance Pharma is UK£0.37 based on Dividend Discount Model

  • Alliance Pharma's UK£0.39 share price indicates it is trading at similar levels as its fair value estimate

  • Analyst price target for APH is UK£0.84, which is 130% above our fair value estimate

In this article we are going to estimate the intrinsic value of Alliance Pharma plc (LON:APH) by taking the forecast future cash flows of the company and discounting them back to today's value. This will be done using the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

ADVERTISEMENT

See our latest analysis for Alliance Pharma

What's The Estimated Valuation?

We have to calculate the value of Alliance Pharma slightly differently to other stocks because it is a pharmaceuticals company. In this approach dividends per share (DPS) are used, as free cash flow is difficult to estimate and often not reported by analysts. Unless a company pays out the majority of its FCF as a dividend, this method will typically underestimate the value of the stock. We use the Gordon Growth Model, which assumes dividend will grow into perpetuity at a rate that can be sustained. For a number of reasons a very conservative growth rate is used that cannot exceed that of a company's Gross Domestic Product (GDP). In this case we used the 5-year average of the 10-year government bond yield (1.4%). The expected dividend per share is then discounted to today's value at a cost of equity of 6.1%. Compared to the current share price of UK£0.4, the company appears around fair value at the time of writing. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

Value Per Share = Expected Dividend Per Share / (Discount Rate - Perpetual Growth Rate)

= UK£0.02 / (6.1% – 1.4%)

= UK£0.4

dcf
dcf

The Assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Alliance Pharma as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.1%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

SWOT Analysis for Alliance Pharma

Strength

  • Debt is well covered by earnings.

Weakness

  • Earnings declined over the past year.

  • Dividend is low compared to the top 25% of dividend payers in the Pharmaceuticals market.

Opportunity

  • Annual earnings are forecast to grow faster than the British market.

  • Good value based on P/S ratio compared to estimated Fair P/S ratio.

Threat

  • Debt is not well covered by operating cash flow.

  • Revenue is forecast to grow slower than 20% per year.

Next Steps:

Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Alliance Pharma, we've compiled three fundamental aspects you should consider:

  1. Risks: As an example, we've found 3 warning signs for Alliance Pharma that you need to consider before investing here.

  2. Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for APH's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors.

  3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the AIM every day. If you want to find the calculation for other stocks just search here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.